Literature DB >> 24816967

Exhaled nitric oxide predicts eosinophilic airway inflammation in COPD.

Kun-Ta Chou1, Kang-Cheng Su, Shiang-Fen Huang, Yi-Han Hsiao, Ching-Min Tseng, Vincent Yi-Fong Su, Shih-Chieh Hung, Diahn-Warng Perng.   

Abstract

PURPOSE: Chronic obstructive pulmonary disease (COPD) with eosinophilic airway inflammation may represent a unique phenotype, possibly with shared features of COPD and asthma. The role of exhaled nitric oxide (eNO) in identifying COPD patients with sputum eosinophilia was examined in this study.
METHODS: Ninety COPD patients without past medical history of asthma or allergic diseases were prospectively enrolled, and their eNO, lung function, and cellular profile of induced sputum were measured. Eosinophil cationic protein and IgE in sputum and venous blood also were determined. Subjects with and without sputum eosinophilia (>3 %) were compared. The role of eNO in the prediction of sputum eosinophilia was assessed in a logistic regression model.
RESULTS: Patients with sputum eosinophilia had significantly higher levels of eNO (29 vs. 18 ppb, p = 0.01) than those without. The difference in serum total IgE (168 vs. 84.9 IU/ml, p = 0.057) and percentages of positive allergen test results (48.3 vs. 29.5 %, p = 0.082) showed a trend toward significance. The sputum eosinophil level was significantly correlated to the eNO level (r = 0.485, p < 0.001). The eNO level at the cutoff of 23.5 ppb had the maximum sum of sensitivity (62.1 %) and specificity (70.5 %). The unadjusted and adjusted odds ratios of a higher eNO level (>23.5 ppb) in the prediction of sputum eosinophilia were 3.909 (confidence interval (CI) 1.542-9.91, p = 0.004) and 4.329 (CI 1.306-14.356, p = 0.017), respectively.
CONCLUSIONS: eNO is a good marker to identify COPD patients with eosinophilic airway inflammation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24816967     DOI: 10.1007/s00408-014-9591-8

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  26 in total

1.  Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease.

Authors:  A Papi; M Romagnoli; S Baraldo; F Braccioni; I Guzzinati; M Saetta; A Ciaccia; L M Fabbri
Journal:  Am J Respir Crit Care Med       Date:  2000-11       Impact factor: 21.405

2.  Comparison of the skin-prick test and Phadia ImmunoCAP as tools to diagnose house-dust mite allergy.

Authors:  Yong Gi Jung; Hyun-Jin Cho; Ga Young Park; Jin-Young Min; Hyo Yeol Kim; Hun-Jong Dhong; Seung Kyu Chung; Seon Woo Kim
Journal:  Am J Rhinol Allergy       Date:  2010 May-Jun       Impact factor: 2.467

3.  Reference ranges for exhaled nitric oxide derived from a random community survey of adults.

Authors:  Justin Travers; Suzanne Marsh; Sarah Aldington; Mathew Williams; Philippa Shirtcliffe; Alison Pritchard; Mark Weatherall; Richard Beasley
Journal:  Am J Respir Crit Care Med       Date:  2007-05-03       Impact factor: 21.405

4.  Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide.

Authors:  Jack F Dummer; Michael J Epton; Jan O Cowan; Julie M Cook; Robin Condliffe; C Erik Landhuis; Andrew D Smith; D Robin Taylor
Journal:  Am J Respir Crit Care Med       Date:  2009-08-06       Impact factor: 21.405

5.  Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.

Authors:  R Siva; R H Green; C E Brightling; M Shelley; B Hargadon; S McKenna; W Monteiro; M Berry; D Parker; A J Wardlaw; I D Pavord
Journal:  Eur Respir J       Date:  2007-02-14       Impact factor: 16.671

6.  Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.

Authors:  C E Brightling; W Monteiro; R Ward; D Parker; M D Morgan; A J Wardlaw; I D Pavord
Journal:  Lancet       Date:  2000-10-28       Impact factor: 79.321

7.  Use of exhaled nitric oxide measurements to guide treatment in chronic asthma.

Authors:  Andrew D Smith; Jan O Cowan; Karen P Brassett; G Peter Herbison; D Robin Taylor
Journal:  N Engl J Med       Date:  2005-05-24       Impact factor: 91.245

8.  Eosinophilic airway inflammation induced by repeated exposure to cigarette smoke.

Authors:  K Matsumoto; H Aizawa; H Inoue; H Koto; S Takata; M Shigyo; H Nakano; N Hara
Journal:  Eur Respir J       Date:  1998-08       Impact factor: 16.671

9.  Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice.

Authors:  Marc Miravitlles; Juan José Soler-Cataluña; Myriam Calle; Joan B Soriano
Journal:  Eur Respir J       Date:  2012-10-11       Impact factor: 16.671

Review 10.  The overlap syndrome of asthma and COPD: what are its features and how important is it?

Authors:  P G Gibson; J L Simpson
Journal:  Thorax       Date:  2009-08       Impact factor: 9.139

View more
  10 in total

1.  Exhaled nitric oxide: Not associated with asthma, symptoms, or spirometry in children with sickle cell anemia.

Authors:  Robyn T Cohen; Mark Rodeghier; Fenella J Kirkham; Carol L Rosen; Jane Kirkby; Michael R DeBaun; Robert C Strunk
Journal:  J Allergy Clin Immunol       Date:  2016-08-09       Impact factor: 10.793

2.  Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.

Authors:  Damien Viglino; Anais Plazanet; Sebastien Bailly; Meriem Benmerad; Ingrid Jullian-Desayes; Renaud Tamisier; Vincent Leroy; Jean-Pierre Zarski; Maxime Maignan; Marie Joyeux-Faure; Jean-Louis Pépin
Journal:  Sci Rep       Date:  2018-11-08       Impact factor: 4.379

3.  Treatment of chronic obstructive pulmonary disease in patients with different fractional exhaled nitric oxide levels.

Authors:  Yao-Kuang Wu; Wen-Lin Su; Chun-Yao Huang; Mei-Chen Yang; Sin-Yi Chen; Chou-Chin Lan
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

4.  Relationship of Blood Eosinophils with Fractional Exhaled Nitric Oxide and Pulmonary Function Parameters in Chronic Obstructive Pulmonary Disease (COPD) Exacerbation.

Authors:  Bin Tang; Dan Huang; Jun Wang; Lin-Lin Luo; Qiu-Gen Li
Journal:  Med Sci Monit       Date:  2020-03-12

5.  Clinical Utility of Central and Peripheral Airway Nitric Oxide in Aging Patients with Stable and Acute Exacerbated Chronic Obstructive Pulmonary Disease.

Authors:  Xiaodong Fan; Nian Zhao; Zhen Yu; Haoda Yu; Bo Yin; Lifei Zou; Yinying Zhao; Xiufen Qian; Xiaoyan Sai; Chu Qin; Congli Fu; Caixia Hu; Tingting Di; Yue Yang; Yan Wu; Tao Bian
Journal:  Int J Gen Med       Date:  2021-02-23

6.  Effect of Inhaled β2-Agonist on Exhaled Nitric Oxide in Chronic Obstructive Pulmonary Disease.

Authors:  Mostafa Amer; Jan Cowan; Andrew Gray; Ben Brockway; Jack Dummer
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

Review 7.  The Relationship between Airway Inflammation and Exacerbation in Chronic Obstructive Pulmonary Disease.

Authors:  Diahn Warng Perng; Pei Ku Chen
Journal:  Tuberc Respir Dis (Seoul)       Date:  2017-09-04

8.  Predictive Value of Exhaled Nitric Oxide and Blood Eosinophil Count in the Assessment of Airway Eosinophilia in COPD.

Authors:  Balazs Antus; Csilla Paska; Imre Barta
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-08-25

9.  A Machine-learning Approach to Forecast Aggravation Risk in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Clinical Indicators.

Authors:  Junfeng Peng; Chuan Chen; Mi Zhou; Xiaohua Xie; Yuqi Zhou; Ching-Hsing Luo
Journal:  Sci Rep       Date:  2020-02-20       Impact factor: 4.379

10.  Low Liver Density Is Linked to Cardiovascular Comorbidity in COPD: An ECLIPSE Cohort Analysis.

Authors:  Damien Viglino; Mickaël Martin; Natalie Almeras; Jean-Pierre Després; Harvey O Coxson; Jean-Louis Pépin; Isabelle Vivodtzev; François Maltais
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-12-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.